Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.

Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.
复制标题

DOI:
10.1016/j.bmcl.2012.06.018
复制
发表时间:
2012-08-01
影响因子:
2.7
通讯作者:
Wood MR
Wood MR
中科院分区:
医学4区
文献类型:
--
作者:
Melancon BJ;Utley TJ;Sevel C;Mattmann ME;Cheung YY;Bridges TM;Morrison RD;Sheffler DJ;Niswender CM;Daniels JS;Conn PJ;Lindsley CW;Wood MR

文献摘要

参考文献

被引文献

相似文献

这封信描述了MLPCN探针分子M1拮抗剂(ML012)通过迭代并行合成方法的持续优化。经过几轮对母体化合物的修饰,我们得到了一种新的氮杂替丁支架,它表现出更好的效力,同时保持了比其他M受体亚型更好的选择性。给出了代表分子7w(VU0452865)和12a(VU0455691)的数据。
This Letter describes the continued optimization of an MLPCN probe molecule M1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented.
DOI: 10.1016/j.ejphar.2008.12.044
发表时间: 2009-03-01
影响因子: 5
作者:
Heinrich, Julia N.;Butera, John A.;Mayer, Scott C.
通讯作者: Mayer, Scott C.
DOI: 10.1021/ml100095k
发表时间: 2010-09-01
影响因子: 4.2
作者:
Kuduk, Scott D.;Chang, Ronald K.;Bilodeau, Mark T.
通讯作者: Bilodeau, Mark T.
DOI: 10.1176/appi.ajp.2008.06091591
发表时间: 2008-08-01
影响因子: 17.7
作者:
Shekhar, Anantha;Potter, William Z.;Felder, Christian C.
通讯作者: Felder, Christian C.
DOI: 10.1016/0896-6273(88)90190-0
发表时间: 1988-07-01
期刊: NEURON
影响因子: 16.2
作者:
BONNER, TI;YOUNG, AC;BUCKLEY, NJ
通讯作者: BUCKLEY, NJ
DOI: 10.1124/mol.109.056531
发表时间: 2009-08-01
影响因子: 3.6
作者:
Sheffler, Douglas J.;Williams, Richard;Conn, P. Jeffrey
通讯作者: Conn, P. Jeffrey